Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2013, Vol. 18 ›› Issue (7): 732-737.

Previous Articles     Next Articles

Mechanisms and protective effect of compound Shanju on aortal injury in spontaneously hypertensive rats

LIU Yan, YANG Jie-ren, HAO Wei, ZHANG Jun-xiu, TANG Li-juan, CHEN Guo-xiang   

  1. Department of Pharmacology, Wannan Medical College, Wuhu 241002, Anhui, China
  • Received:2012-09-06 Revised:2012-12-22 Online:2013-07-26 Published:2013-06-20

Abstract: AIM: To observe the protective effect of compound Shanju on the aortal injury in spontaneously hypertensive rats (SHRs) and explore its conceivable mechanisms.METHODS: SHRs (35) were randomly divided into SHR model (distilled water 5 mL·kg-1·d-1,n=7) group, compound Shanju with high, medium and low dosages (0.45, 0.15, and 0.05 g·kg-1·d-1,n=7, respectively) groups, and captopril (0.03 g·kg-1·d-1,n=7) positive control group. In addition, the WKY (distilled water 5 mL·kg-1·d-1,n=7) negative control group was established. All animals were administrated for 16 weeks. Blood pressure was measured by tail cuff for 16 weeks fortnightly interval with all animals. After 16 weeks, the primary pathologic changes of aorta were observed by HE staining, and collagen deposition was stained by Masson visually. The expression of eNOS and TGF-β1 protein were measured by immunohistochemistry.RESULTS: With the increase dose of compound Shanju, the aortal pathological damage had been improved, the area of collage deposition had been ameliorated gradually in aortal tunica media. The expression of TGF-β1 protein downregulated and that of eNOS protein upregulated inch by inch.CONCLUSION: Compound Shanju can significantly ameliorate the aortal injury and collagen deposition, suggesting this medicine may protect the aorta from injury through downregulating TGF-β1 and upregulating eNOS protein expression.

Key words: Compound Shanju, Spontaneously hypertensive rats, Collagen deposition, TGF-β1, eNOS

CLC Number: